+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-12-29Number of Pages: 74

CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).  CINV significantly affects the treatment of patients undergoing chemotherapy. Two major subtypes of CINV are acute CINV (occurs within 24 hours of chemotherapy) and delayed CINV (occurs between 24 hours and five days after treatment). Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the examples of currently available drugs to manage both CINV subtypes. In coming years, the CINV drugs market is expected to witness the introduction of two new drugs, namely, SUSTOL (extended release generic granisetron) and rolapitant.

The world is witnessing a continuous rise in the incidence of various types of cancer, which results in increasing number of patients undergoing chemotherapy. According to the online cancer database GLOBOCAN by the International Agency for Research on Cancer (IARC), globally 14.1 million people were diagnosed with cancer (excluding non-melanoma skin cancer) in 2012 as compared to 12.7 million in 2008. The incidence rate is projected to reach 15.2 million and 17.1 million in 2015 and 2020, respectively. These facts indicate that growing incidence of various types of cancer is likely to induce oncologists to prescribe chemotherapy to their patients for the effective treatment of cancer, thereby driving the CINV drugs market. Usually 25% to 30% patients with cancer receive chemotherapy as a treatment option and 70% to 80% of these patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms.

The approval of new drugs such as rolapitant and SUSTOL (APF-530) would also drive the growth of the CINV drugs market during the forecast period from 2014 to 2020. These pipeline drugs have shown better efficacy than existing drugs during their clinical study. Therefore, the anticipated launch of these more efficacious pipeline drugs during the projected period is likely to encourage physicians to prescribe these new drugs over existing drugs. However, the patent expiry of leading drugs Aloxi and Emend are expected to have significant impact on the revenue of overall CINV drugs market during the forecast period from 2014 to 2020.

North America was the largest regional market for CINV drugs in 2013 in terms of revenue and is expected to retain its position throughout the forecast period, primarily due to the anticipated approval of rolapitant and SUSTOL in 2015 and 2016, respectively. Europe represented the second largest market for CINV drugs after North America in 2013. The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. The high incidence of various types of cancer in Asia-Pacific and Rest of the World (RoW) represents both these regions as potential markets for CINV drugs. The economic emergence of countries such as India and China, along with their continuously improving health care infrastructure, is expected to play a key role in driving the CINV market growth in Asia-Pacific region.

GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. are among the major players operating in the CINV drugs market. In addition to these players, the market is also characterized by a number of generic manufacturers such as Baxter Healthcare, Barr Laboratories, Inc., Sun Pharma, Sandoz (Novartis AG), Mylan Pharmaceuticals, Inc., Orchid Healthcare and Teva Pharmaceuticals.

cinv-market

Chemotherapy induced nausea and vomiting (CINV) refers to the nausea and vomiting associated with cancer chemotherapy. Various sources indicate that approximately 70% to 80% cancer patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms. Chemotherapy induced nausea and vomiting is an extremely debilitating condition. Although there are currently a number of drugs available to manage CINV, they do not effectively address the symptoms of this condition. The report on CINV existing and pipeline drugs market offers an insightful and in-depth assessment of the current as well as future market potential of CINV drugs. Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the major currently available drugs extensively studied in the report. The historical market size and forecast for each of these drugs (except for Akynzeo, as the U.S. Food and Drug Administration (FDA) approved it only in October 2014) in terms of revenue (USD Million) has been provided in the report for the period from 2012 to 2020. In addition, the compounded annual growth rate (CAGR) for each of these drugs has been provided in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. The report also studies the CINV patient pool for each of these drugs. The market size and CAGR for Akynzeo have been determined for the years from 2015 to 2020.

The report also provides extensive analysis of the pipeline drugs SUSTOL (extended release granisetron injection) and rolapitant, including the status of current clinical trials and future sales projection in terms of USD million. The future sales projection of both these pipeline drugs has also been provided for the North American and European regions. The study also provides estimated patient pool for both these pipeline drugs, broken down by North America and Europe.

In this research study, the global market for CINV drugs has been geographically segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The CINV drugs market size and forecast in terms of revenue for each region has been provided for the period from 2012 to 2020 along with the CAGR for the forecast period from 2014 to 2020. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities. The market overview chapter provides information such as major subtypes of CINV, the etiology of CINV, the pathogenesis of CINV, major emetogenic chemotherapeutic agents, treatment recommendations for CINV and unmet needs in the CINV market. A section on event impact analysis has also been provided in the market overview chapter of the report on CINV existing and pipeline drugs market.

The report on chemotherapy induced nausea and vomiting drugs market also includes a section on the competitive landscape of the market, wherein the qualitative analysis of leading players in the global CINV drugs market is presented. The report concludes with the profiles of major players in the chemotherapy induced nausea and vomiting drugs market such as GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. Each company profile comprises information such as company overview, financial overview (selling, general and administrative expenses, research and development expenses and annual revenue for consecutive three years 2011, 2012 and 2013), current and pipeline product portfolio, business strategies and recent developments.

The global CINV existing and pipeline drugs market is segmented as follows:

CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Major Drugs
  • Aloxi (palonosetron)
  • Zofran Generic (ondansetron)
  • Kytril Generic (granisetron)
  • Emend (aprepitant)
  • Akynzeo (netupitant-palonosetron)
  • SUSTOL (extended release granisetron injection)
  • Rolapitant
 CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)


 
 
Back To Top